Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Sanatoriumi Tsqaltubo | Healthcare Services | 35.6% | 93rd pct | 268 |
| Avtandil Qambarashvilis… | Healthcare Services | 5.1% | 35th pct | 268 |
| Mmedi22 | Healthcare Services | -2.5% | 21st pct | 268 |
| Kobuletis Sameditsino T… | Healthcare Services | -23.6% | 7th pct | 268 |
| New Clinic | Healthcare Services | — | no FY data | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 4 of 5 peers filed FY2024. Switch to FY2023 (5 of 5).
| Ratio — FY 2024 | Mmedi22 | Kobuletis Sameditsino T… | Avtandil Qambarashvilis… | Sanatoriumi Tsqaltubo | New Clinic |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 19.5% | -5.7% | 83.8% | 91.9% | — |
| EBITDA Margin | -2.5% | -23.6% | 5.1% | 35.6% | — |
| EBITDAR | -105 | -901 | 215 | 1,660 | — |
| EBITDAR Margin | -2.5% | -21.3% | 5.1% | 39.8% | — |
| EBIT Margin | -12.6% | -34.4% | 0.1% | 15.6% | — |
| Net Profit Margin | -15.9% | -34.5% | -2.3% | 0.2% | — |
| Operating Expense % of Sales | 21.9% | 17.9% | 78.7% | 56.3% | — |
| Returns | |||||
| Return on Assets (ROA) | -15.2% | -41.2% | -1.6% | 0.0% | — |
| Return on Equity (ROE) | -25.9% | -57.9% | -2.1% | 0.1% | — |
| ROIC [EBIT / Invested Capital] | |||||
| -15.0% |
| -59.8% |
| 0.1% |
| 4.0% |
| — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 21.8% | 0.0% | 11.7% | 50.1% | — |
| Debt-to-Equity | 0.37x | 0.00x | 0.16x | 1.09x | — |
| Debt-to-EBITDA | N/A | N/A | 3.36x | 5.66x | — |
| Equity-to-Assets | 58.8% | 71.1% | 74.7% | 46.0% | — |
| Net Debt | 957 | -83 | 720 | 8,379 | — |
| Cash & Equivalents | 14 | 83 | 2 | 20 | — |
| Total Debt | 971 | N/A | 722 | 8,399 | — |
| Liquidity & working capital | |||||
| Current Ratio | 0.67x | 0.97x | 2.08x | 0.95x | — |
| Quick Ratio | 0.67x | 0.97x | 2.08x | 0.95x | — |
| Cash Ratio | 0.01x | 0.09x | 0.00x | 0.03x | — |
| Total Current Assets | 1,239 | 899 | 1,292 | 644 | — |
| Total Current Liabilities | 1,837 | 925 | 622 | 678 | — |
| Inventory | N/A | N/A | N/A | N/A | — |
| Trade Receivables | 1,100 | 788 | 1,292 | 544 | — |
| Trade Payables | 700 | 289 | 622 | 444 | — |
| Net Working Capital | -598 | -25 | 670 | -34 | — |
| Net Working Capital % of Revenue | -14.1% | -0.6% | 16.0% | -0.8% | — |
| Trade Working Capital | 400 | 499 | 670 | 100 | — |
| Trade Working Capital % of Revenue | 9.4% | 11.8% | 16.0% | 2.4% | — |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | — |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | N/A | N/A | N/A | — |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A | N/A | — |
| Receivables Turnover | 3.87x | 5.38x | 3.25x | 7.66x | — |
| Days Sales Outstanding (DSO) | 94.4 | 67.8 | 112.3 | 47.6 | — |
| Payables Turnover | 4.90x | 15.50x | 1.09x | 0.76x | — |
| Days Payable Outstanding (DPO) | 74.6 | 23.6 | 334.5 | 477.8 | — |
| Cash Conversion Cycle | 19.8 days | 44.3 days | -222.3 days | -430.2 days | — |
| Asset Turnover | 0.95x | 1.19x | 0.68x | 0.25x | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | 197 | N/A | N/A | 748 | — |
| Free Cash Flow (OCF − Capex proxy) | 143 | N/A | N/A | -9 | — |
| Cash Conversion (OCF / EBITDA) | N/A | N/A | N/A | 50.4% | — |
| Dividends Declared | N/A | N/A | N/A | N/A | — |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | — |